1. Key Insights 2. Autism Spectrum Disorder Market Overview at a Glance 2.1. Market Share (%) Distribution of ASD in 2016 2.2. Market Share (%) Distribution of ASD in 2027 3. Disease Overview: Autism Spectrum Disorder 3.1. Introduction 3.2. Types of ASD 3.3. Etiology of Autism Spectrum Disorder 3.4. Pathophysiology of Autism Spectrum Disorder 3.5. Signs and Symptoms 3.6. Diagnosis 3.7. Diagnostic Guidelines 3.7.1. Diagnostic Criteria 3.7.2. American Academy of Neurology and the Child Neurology Society 3.7.3. The National Institute for Health and Care Excellence (NICE) 3.8. Diagnostic Algorithm 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. 7MM Total Diagnosed Prevalent Cases of Autism Spectrum Disorder 5. Country Wise-Epidemiology of Autism Spectrum Disorder 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Diagnosed Prevalent Cases of ASD in the United States 5.1.3. Gender Specific Diagnosed Prevalent cases of ASD in the United States 5.1.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in the United States 5.2. EU5 5.3. Germany 5.3.1. Assumptions and Rationale 5.3.2. Diagnosed Prevalent Cases of ASD in Children in Germany 5.3.3. Gender Specific Diagnosed Prevalent Cases of ASD in Germany 5.3.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in Germany 5.4. France 5.4.1. Assumptions and Rationale 5.4.2. Diagnosed Prevalent Cases of ASD in France 5.4.3. Gender Specific Diagnosed Prevalent Cases of ASD in France 5.4.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in France 5.5. Italy 5.5.1. Assumptions and Rationale 5.5.2. Diagnosed Prevalent Cases of ASD in Italy 5.5.3. Gender Specific Diagnosed Prevalent Cases of ASD in Italy 5.5.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in Italy 5.6. Spain 5.6.1. Assumptions and Rationale 5.6.2. Diagnosed Prevalent Cases of ASD in Spain 5.6.3. Gender Specific Diagnosed Prevalent Cases of ASD in Spain 5.6.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in Spain 5.7. United Kingdom 5.7.1. Assumptions and Rationale 5.7.2. Diagnosed Prevalent Cases of ASD in the United Kingdom 5.7.3. Gender Specific Diagnosed Prevalent Cases of ASD in the United Kingdom 5.7.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in the United Kingdom 5.8. Japan 5.8.1. Assumptions and Rationale 5.8.2. Diagnosed Prevalent Cases of ASD in Japan 5.8.3. Gender Specific Diagnosed Prevalent Cases of ASD in Japan 5.8.4. Subtype-Specific Diagnosed Prevalent Cases of ASD in Japan 6. Treatment Practices 7. Treatment Guidelines and Recommendations 7.1. American Academy of Child & Adolescent Psychiatry 7.2. National Institute for Health and Care Excellence (NICE) 8. Treatment Algorithm 9. Unmet Needs 10. Marketed Drugs 10.1. Risperdal: Johnson and Johnson 10.1.1. Drug Description 10.1.2. Regulatory Milestones 10.1.3. Advantages & Disadvantages 10.1.4. Clinical Development 10.1.5. Safety and Efficacy 10.1.6. Product Profile 10.2. Abilify: Otsuka Pharmaceutical 10.2.1. Drug Description 10.2.2. Regulatory Milestones 10.2.3. Advantages & Disadvantages 10.2.4. Clinical Development 10.2.5. Safety and Efficacy 10.2.6. Product Profile 10.3. Slenyto: Neurim Pharmaceuticals 10.3.1. Drug Description 10.3.2. Regulatory Milestones 10.3.3. Advantages & Disadvantages 10.3.4. Clinical Development 10.3.5. Safety and Efficacy 10.3.6. Product Profile 11. Emerging Therapies 11.1. Key cross competition- Emerging Therapies 11.2. Balovaptan: Roche 11.2.1. Product Description 11.2.2. Other Developmental Activities 11.2.3. Clinical Development 11.2.4. Safety and Efficacy 11.2.5. Product Profile 11.3. Bumetanide: Neurochlore/Servier 11.3.1. Product Description 11.3.2. Other Developmental Activities 11.3.3. Clinical Development 11.3.4. Safety and Efficacy 11.3.5. Product Profile 11.4. CM-AT: Curemark 11.4.1. Product Description 11.4.2. Other Developmental Activities 11.4.3. Clinical Development 11.4.4. Safety and Efficacy 11.4.5. Product Profile 11.5. L1-79: Yamo Pharmaceuticals 11.5.1. Product Description 11.5.2. Other Developmental Activities 11.5.3. Clinical Development 11.5.4. Safety and Efficacy 11.5.5. Product Profile 12. Autism Spectrum Disorder: 7 Major Market Analysis 12.1. Key Findings 12.2. Market Size of Autism Spectrum Disorder in 7MM 13. Market Outlook by Country 14. The United States: Market Outlook 14.1.1. United States Market Size 14.1.2. Total Market size of Autism Spectrum Disorder 14.1.3. Autism Spectrum Disorder Market by Therapies 15. EU-5 Countries: Market Outlook 15.1. Germany 15.1.1. Total Market size of Autism Spectrum Disorder 15.1.2. Autism Spectrum Disorder Market by Therapies 15.2. France 15.2.1. Total Market size of Autism Spectrum Disorder 15.2.2. Autism Spectrum Disorder Market by Therapies 15.3. Italy 15.3.1. Total Market size of Autism Spectrum Disorder 15.3.2. Autism Spectrum Disorder Market by Therapies 15.4. Spain 15.4.1. Total Market size of Autism Spectrum Disorder 15.4.2. Autism Spectrum Disorder Market by Therapies 15.5. United Kingdom 15.5.1. Total Market size of Autism Spectrum Disorder 15.5.2. Autism Spectrum Disorder Market by Therapies 16. Japan: Market Outlook 16.1. Total Market size of Autism Spectrum Disorder 16.2. Autism Spectrum Disorder Market by Therapies 17. Market Drivers 18. Market Barriers 19. Appendix 19.1. Report Methodology 20. DelveInsight Capabilities 21. Disclaimer 22. About DelveInsight

Table 1: Single gene disorders with the high rate of autism Table 2: Changes in the diagnostic criteria for the PDDs in the DSM-5 (adapted from Ozonoff) Table 3: Differential diagnosis of language disorders Table 4: Severity Levels of Autism Spectrum Disorder Table 5: Severity Levels of Autism Spectrum Disorder Table 6: Organisation and delivery of care Table 7: NICE Guideline, Core Autism Features Table 8: 7MM Total Diagnosed Prevalent Cases of Autism Spectrum Disorder (2016-2027) Table 9: Diagnosed Prevalent Cases of ASD in the United States (2016-2027) Table 10: Gender Specific Diagnosed Prevalent Cases of ASD in the United States (2016-2027) Table 11: Subtype-Specific Diagnosed Prevalent Cases of ASD in the United States (2016-2027) Table 12: Diagnosed Prevalent Cases of Autism Spectrum Disorder in Germany (2016-2027) Table 13: Gender Specific Diagnosed Prevalent Cases of ASD in Germany (2016-2027) Table 14: Subtype-Specific Diagnosed Prevalent Cases of ASD in Germany (2016-2027) Table 15: Diagnosed Prevalent Cases of Autism Spectrum Disorder in France (2016-2027) Table 16: Gender Specific Diagnosed Prevalent Cases of ASD in France (2016-2027) Table 17: Subtype-Specific Diagnosed Prevalent Cases of ASD in France (2016-2027) Table 18: Diagnosed Prevalent Cases of ASD in Italy (2016-2027) Table 19: Gender Specific Diagnosed Prevalent Cases of ASD in Italy (2016-2027) Table 20: Subtype-Specific Diagnosed Prevalent Cases of ASD in Italy (2016-2027) Table 21: Diagnosed Prevalent Cases of ASD in Spain (2016-2027) Table 22: Gender Specific Diagnosed Prevalent Cases of ASD in Spain (2016-2027) Table 23: Subtype-Specific Diagnosed Prevalent Cases of ASD in Spain (2016-2027) Table 24: Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027) Table 25: Gender Specific Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027) Table 26: Subtype-Specific Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027) Table 27: Diagnosed Prevalent Cases of ASD in Japan (2016-2027) Table 28: Gender Specific Diagnosed Prevalent Cases of ASD in Japan (2016-2027) Table 29: Subtype-Specific Diagnosed Prevalent Cases of ASD in Japan (2016-2027) Table 30: Essential characteristics of effective interventions for children with autism spectrum disorder Table 31: Consensus recommendations of pharmacological treatment of co-occurring conditions and symptoms in children and adults with ASD Table 32: Recommendations Table 33: Antipsychotic medication for behaviour that challenges Table 34: Sleep problems Table 35: What is needed to inform the families in care? Table 36: Key points for the general paediatrician Table 37: Risperdal, Clinical Trial Description, 2018 Table 38: Abilify, Clinical Trial Description, 2018 Table 39: Slenyto, Clinical Trial Description, 2018 Table 40: Key cross competition- Emerging Therapies Table 41: Balovaptan, Clinical Trial Description, 2018 Table 42: Bumetanide, Clinical Trial Description, 2018 Table 43: CM-AT, Clinical Trial Description, 2018 Table 44: L1-79, Clinical Trial Description, 2018 Table 45: 7 Major Market Size of Autism Spectrum Disorder in USD Million (2016-2027) Table 46: United States Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Table 47: United States Market Size of ASD by Therapies in USD Million (2016-2027) Table 48: Germany Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Table 49: Germany Market Size of ASD by Therapies in USD Million (2016-2027) Table 50: France Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Table 51: France Market Size of ASD by Therapies in USD Million (2016-2027) Table 52: Italy Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Table 53: Italy Market Size of ASD by Therapies in USD Million (2016-2027) Table 54: Spain Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Table 55: Spain Market Size of ASD by Therapies in USD Million (2016-2027) Table 56: United Kingdom Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Table 57: UK Market Size of ASD by Therapies in USD Million (2016-2027) Table 58: Japan Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Table 59:Japan Market Size of ASD by Therapies in USD Million (2016-2027) Figure 1: Types of Autism Spectrum Disorder Figure 2: Converging Mechanisms of Autism Spectrum Disorder Figure 3: Types of Autism Spectrum Disorder Figure 4: 7MM Total Diagnosed Prevalent Cases of Autism Spectrum Disorder (2016-2027) Figure 5: Diagnosed Prevalent Cases of ASD in the United States (2016-2027) Figure 6: Gender Specific Diagnosed Prevalent Cases of ASD in the United States (2016-2027) Figure 7: Subtype-Specific Diagnosed Prevalent Cases of ASD in the United States (2016-2027) Figure 8: Diagnosed Prevalent Cases of Autism Spectrum Disorder in Germany (2016-2027) Figure 9: Gender Specific Diagnosed Prevalent Cases of ASD in Germany (2016-2027) Figure 10: Subtype-Specific Diagnosed Prevalent Cases of ASD in Germany (2016-2027) Figure 11: Diagnosed Prevalent Cases of Autism Spectrum Disorder in France (2016-2027) Figure 12: Gender Specific Diagnosed Prevalent Cases of ASD in France (2016-2027) Figure 13: Subtype-Specific Diagnosed Prevalent Cases of ASD in France (2016-2027) Figure 14: Diagnosed Prevalent Cases of ASD in Italy (2016-2027) Figure 15: Gender Specific Diagnosed Prevalent Cases of ASD in Italy (2016-2027) Figure 16: Subtype-Specific Diagnosed Prevalent Cases of ASD in Italy (2016-2027) Figure 17: Diagnosed Prevalent Cases of ASD in Spain (2016-2027) Figure 18: Gender Specific Diagnosed Prevalent Cases of ASD in Spain (2016-2027) Figure 19: Subtype-Specific Diagnosed Prevalent Cases of ASD in Spain (2016-2027) Figure 20: Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027) Figure 21: Gender Specific Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027) Figure 22: Subtype-Specific Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027) Figure 23: Diagnosed Prevalent Cases of ASD in Japan (2016-2027) Figure 24: Gender Specific Diagnosed Prevalent Cases of ASD in Japan (2016-2027) Figure 25: Subtype-Specific Diagnosed Prevalent Cases of ASD in Japan (2016-2027) Figure 26: Unmet Needs for Autism Spectrum Disorder Figure 27: 7 Major Market Size of Autism Spectrum Disorder in USD Million (2016-2027) Figure 28: United States Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Figure 29: United States Market Size of ASD by Therapies in USD Million (2016-2027) Figure 30: Germany Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Figure 31: Germany Market Size of ASD by Therapies in USD Million (2016-2027) Figure 32: France Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Figure 33: France Market Size of ASD by Therapies in USD Million (2016-2027) Figure 34: Italy Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Figure 35: Italy Market Size of ASD by Therapies in USD Million (2016-2027) Figure 36: Spain Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Figure 37: Spain Market Size of ASD by Therapies in USD Million (2016-2027) Figure 38: United Kingdom Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Figure 39: UK Market Size of ASD by Therapies in USD Million (2016-2027) Figure 40: Japan Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) Figure 41: Japan Market Size of ASD by Therapies in USD Million (2016-2027) Figure 42: Market Drivers Figure 43:Market Barriers

Roche Neurochlore/Servier Curemark Yamo Pharmaceuticals